Background-Up to 30% of patients with severe aortic stenosis (SAS; indexed aortic valve area <0.6 cm 2 /m 2 ) present with low transvalvular gradient despite a normal left ventricular ejection fraction. Presently, there is intense controversy as to the prognostic implications of such findings. Accordingly, the aim of the present work was to compare the natural history of patients with paradoxical low-gradient (PLG) or high-gradient (HG) SAS. Methods and Results-We prospectively studied 349 patients with SAS and preserved left ventricular ejection fraction.
I n ≈30% 1-3 of patients referred for echocardiographic evaluation for the severity of aortic stenosis (AS), the clinician is confronted with lower-than-expected peak transvalvular velocities and mean pressure gradients despite apparently severe AS (SAS) based on aortic valve area (AVA). Because transvalvular pressure gradients are notably flow-dependent, it has long been recognized that patients with left ventricular (LV) dysfunction and low cardiac output may present with relatively low transvalvular pressure gradients, despite SAS. 4 Recently, several retrospective studies 5, 6 have shown that such low transvalvular gradients can also be observed in patients with preserved LV ejection fraction (LVEF), presumably as a result of small cavity sizes and low stroke volumes, typically <35 mL/m 2 . Because it is observed in patients with normal LVEF, this new subset of SAS has been termed paradoxical low-gradient (PLG) SAS, in contrast with the low flow-low gradient (LF-LG) subset seen in patients with LV dysfunction.
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There is considerable debate as to the clinical significance of this new AS constellation. Some authors indeed consider this new entity as a more advanced form of AS, [5] [6] [7] with increased interstitial fibrosis, reduced LV longitudinal function, 8, 9 and poor prognosis, whereas others think it represents a relatively benign form of AS, with an outcome similar to that of moderate AS. 1 In view of this controversy, the objective of the present study was to compare the natural history of patients with PLG-SAS with that of patients with a high-gradient (HG) SAS. By censoring patients at the time of aortic valve replacement (AVR), we sought to minimize the effects of treatment and of its potential differential use in the 2 groups on outcome. Because in AS patients natural history is dramatically influenced by symptoms, we also paid a particular attention to the outcome of initially asymptomatic patients. Finally, we investigated how transvalvular gradients evolved over time in the 2 groups, to test which of the 2 conditions could be considered as a more advanced stage of the disease.
Methods

Patient Population
Since January 2000, all patients with valvular heart disease referred to the Cardiovascular Department of the Cliniques Universitaires St-Luc are enrolled into a prospective registry. Baseline demographics, clinical features, and echocardiographic data are collected and stored in an electronic database. Subsequent clinical and echocardiographic data are regularly updated. We obtained approval of the valve disease registry by our institutional review board, as well as a waiver of informed consent for retrospective data handling. The study was conducted in accordance with institutional policies, national legal requirements, and the revised Helsinki declaration.
Between January 1, 2000, and November 30, 2010, 1131 patients with SAS, defined as an AVA <1 cm 2 , an indexed AVA <0.6 cm 2 /m 2 , and a preserved LVEF ≥50%, were enrolled into the registry. From this initial cohort, 782 patients were excluded for the following reasons: AVR <3 months of the index diagnosis (n=579), missing clinical or demographic data (n=36), incomplete or poor quality echocardiographic images (n=34), more than moderate aortic regurgitation or mitral valve disease (n=8), active malignancies (n=31), advanced-stage cognitive disorders (n=8), and severe renal failure defined as a glomerular filtration rate, according the Cockroft and Gault formula, of <30 mL/min (n=86). Patients with coronary artery disease were not excluded. Coronary artery disease was considered to be present if any of the following were present: previous myocardial infarction, angiographic evidence of coronary artery disease, previous coronary artery bypass surgery, or percutaneous coronary intervention. The final study population thus consisted of 349 patients, of which 144 displayed a mean transaortic pressure gradient >40 mm Hg (HG-SAS) and 205 had a mean transaortic pressure gradient ≤40 mm Hg (PLG-SAS).
Symptomatic Status
Symptoms, including heart failure, angina, and syncope during exertion, were noted as recorded in the registry database. The functional status about dyspnea, heart failure, angina, and syncope was graded according to the New York Heart Association (NYHA) classification at the time of inclusion into the registry. Patients were considered to be in NYHA class I if they were free of any symptoms; in NYHA class II if they complained of mild symptoms (ie, mild shortness of breath or angina) and slight limitation during ordinary activity; in NYHA class III if they had experienced limitation in activity because of heart failure or anginal symptoms during less-than-ordinary activity; and in NYHA class IV if they had experienced heart failure or anginal symptoms while at rest. Patients with exercise-induced syncope were considered to be in NYHA class III. Similarly, patients who experienced transient NYHA class III or IV symptoms and did return in lower NYHA classes because of medical treatment were considered to be in either NYHA class III or IV.
Echocardiography
Echocardiographic data were obtained with commercially available ultrasound systems. All patients underwent a comprehensive examination, including M-mode and 2-dimensional echocardiography, as well as Doppler examinations. All tests were conducted by experienced sonographers. Multiple transducer positions were systematically used to record maximal instantaneous and mean pressure gradients across the aortic valve. AVA was calculated by use of the continuity equation. In patients with atrial fibrillation, 5 consecutive beats were systematically averaged.
LV volumes and LVEF were calculated by use of the biplane Simpson method; LV mass according to the Devereux formula; and left atrial volume using biplane area-length method. 10 Systolic pulmonary artery pressure was considered to be equal to the systolic transtricuspid pressure gradient as calculated by use of the modified Bernoulli equation. No attempt was made to estimate right atrial pressure.
Follow-Up
The most recent information on events was obtained during the first semester of 2013. Cardiac events and causes of death were ascertained by contacting the patients' physicians, the patients themselves, or their family or by reviewing death certificates. Follow-up was 100% complete.
Statistical Analysis
All analyses were performed using the SPSS v19.0 (SPSS Inc, IBM, Chicago, IL). Continuous variables were expressed as mean±1 SD and were compared using the Student t test. Categorical variables were expressed as counts and percentages and compared using the χ 2 test. Follow-up times were expressed as median and range. Survival curves were computed using the Kaplan-Meier method and compared using the log-rank χ 2 test. When reporting on the natural history of SAS, follow-up started at the time of the first echocardiographic examination, and patients undergoing AVR during follow-up were censored at the time of surgery. When reporting on postoperative survival, follow-up started on the day of surgery. For each patient included in the study, the corresponding average age-specific annual mortality rates of the Belgian general population were obtained. Finally, a Cox model was used to adjust for the effects of baseline patient characteristics on their natural history. For this purpose, all clinical and echocardiographic univariate correlates of the natural history (P<0.10) were proposed for inclusion into a stepwise multivariate Cox model. To avoid collinearity, the correlation coefficients between covariates were calculated. In case of collinearity (r value >0.90), only 1 of the 2 covariates was considered in the multivariate model. Relative hazards ratio for each specific covariate of the final model was computed as the exponential of the regression coefficient. All tests were 2-sided and a P value ≤0.05 was considered significant.
Results
The strategy of the analysis was first to assess baseline characteristics in patients with HG-SAS and PLG-SAS, stratified according to their symptomatic status, to evaluate factors independently associated with outcome and finally to compare the natural history of the disease according to the factors identified in the Cox survival analysis. As in previous natural history studies, patients were censored at the time of treatment, that is, AVR.
Baseline clinical, hemodynamic, and echocardiographic characteristics of the entire population and of the subgroup of initially asymptomatic or minimally symptomatic patients (NYHA I to II) are shown in Tables 1 and 2, respectively. For comparison, the baseline characteristics of the 579 who were operated <3 months of the index diagnosis are provided in the the Data Supplement. Patients with HG-SAS and PLG-SAS had similar clinical and demographic characteristics, except for diabetes mellitus and atrial fibrillation, which were more prevalent in PLG-SAS than in HG-SAS. From an echocardiographic point of view, all patients demonstrated calcified aortic valves. No attempt was made to differentiate tricuspid from bicuspid aortic valves. Patients with PLG-SAS had larger indexed AVAs and energy loss indexes, reduced LV end-diastolic dimensions and volumes, lower stroke volumes, and a higher valvuloarterial impedance compared with patients with HG-SAS.
Patients with PLG-SAS were further stratified into groups with normal flow (NF) and LF, using the previously described cut-off value of 35 mL/m 2 . 5 As shown in Table 3 , patients with LF-PLG-SAS had similar baseline characteristics as those with NF-PLG-SAS, except for atrial fibrillation, which was more prevalent in LF-PLG-SAS.
Clinical Outcomes
During a median follow-up of 28 months (range, 3-140 months), there were 92 AVRs and 148 deaths, of which 123 were of cardiovascular origin (heart failure in 57, sudden cardiac death in 24, stroke in 10, acute coronary syndrome in 4, pulmonary embolism in 4, endocarditis in 2, aortic dissection in 1, miscellaneous in 21). In patients who underwent AVR during follow-up, there were 17 postoperative deaths: 3 within 30 days of AVR (1 cardiogenic shock, 1 sepsis, 1 stroke), and 14 late deaths (heart failure in 3, sepsis in 2, sudden cardiac death in 2, acute coronary syndrome in 1, postoperative death during reoperation in 1, and cancer in 5).
The natural history of the entire population and of the NYHA I to II subgroup is shown in Figures 1 and 2 . Natural history (overall Kaplan-Meier estimated survival at 4 years) was significantly better in PLG-SAS than in HG-SAS, both in the overall population (48±5% versus 31±5%; P<0.01) and in the NYHA I to II subgroup (59±5% versus 35±7%; P=0.02). By contrast, transvalvular flow had no significant impact on the natural history of SAS, neither in the overall population (42±5% in LF-SAS versus 40±5% in NF-SAS; P=0.98) nor in the NYHA I to II subgroup (55±7% in LF-SAS versus 47±6% in NF-SAS; P=0.50). This was also true in the subgroups with either HG-SAS (29±8% in LF-HG-SAS versus 32±6% in NF-HG-SAS; P=0.52) or PLG SAS (48±6% in LF-PLG-SAS versus 48±7% in NF-PLG-SAS; P=0.70; see the Data Supplement for survival curves).
Patients with PLG-SAS had a lower incidence of AVR than those with HG-SAS (7±2% versus 17±3% at 1 year; P<0.01; and 33±5% versus 42±6% at 4 years; P=0.04). Survival free of death or AVR was significantly better in PLG-SAS than in HG-SAS, both in the overall population (32±4% versus 18±3%; P<0.01) and in the NYHA I to II subgroup (35±5% versus 17±5%; P=0.002).
Predictors of Outcome
The results of the uni-and multivariate Cox survival analyses in the entire population and in the NYHA I to II subgroup are shown in Tables 4 and 5. In the whole population, 5 variables were found to be independently associated with outcome: age, left atrial volume, presence of chronic obstructive pulmonary disease, diabetes mellitus, and NYHA class. When considering the NYHA I to II subgroup (n=220), the mean transaortic pressure gradient, age, diabetes mellitus, and left atrial volume were found to independently predict outcome. By contrast, transvalvular flow did not significantly influence outcome. Values are n (%) or mean±SD. AVAi indicates indexed aortic valve area; GFR, glomerular filtration rate; HG-SAS, high-gradient severe aortic stenosis (SAS); LA, left atrial; LV, left ventricular; LVEDVi, LV end-diastolic volume index; NYHA, New York Heart Association; and PLG-SAS, paradoxical low-gradient SAS.
Impact of Atrial Fibrillation
Because atrial fibrillation reduces transvalvular flow and flow rates and at the same time is an important confounding factor in prognostic studies, we conducted a separate analysis in patients without atrial fibrillation. In patients in sinus rhythm, 4-year natural history remained significantly better in PLG-SAS than in HG-SAS, both in the overall population (P=0.001) and in the NYHA I to II subgroup (P=0.005; see the Data Supplement).
Outcome With and Without AVR
AVR resulted in a significantly better survival in both groups (Figure 3 ). The magnitude of the protective effect of AVR tended to be more important in the HG-SAS than in the PLG-SAS group, mainly because of the better outcome of unoperated PLG-SAS patients as compared with unoperated HG-SAS patients.
Progression and Outcome According to the Last Available Echocardiogram
Data from the last available complete follow-up echocardiogram before death or AVR showed that in the 102 initially PLG-SAS patients with available follow-up echocardiographic data, the severity of SAS had progressed significantly, their mean gradient increasing from 29±6 to 38±11 mm Hg (P<0.001). At the end of follow-up, 46 (45%) had reached the stage of HG-SAS, 38 (37%) remained at the stage of PLG-SAS but significantly increased their mean transvalvular gradient (from 26±5 to 32±5 mm Hg; P<0.001), and 18 either had maintained or decreased their mean gradient over time. Interestingly, in 11 out of these 18 patients, the reduction in mean transvalvular gradients was contemporary to the development of LV dysfunction. Figure 4 shows individual changes in mean transaortic gradient between baseline and last echocardiograpic follow-up in patients with initial PLG-SAS. Survival free of becoming HG-SAS in the same patients is shown in the Data Supplement.
In the 51 initially HG-SAS patients with available followup echocardiographic data, mean transvalvular gradients increased in the 42 patients whose LVEF remained ≥50% (from 53±10 to 66±43 mm Hg; P=0.05). It also increased, albeit to a lesser extent, in most of the patients who developed LV dysfunction, with the exception of 2 patients who developed LF-LG-SAS. On average, annualized progression rates were similar in PLG-SAS and HG-SAS (5±6 versus 5±10 mm Hg/year; P=0.91).
Discussion
The aim of the present study was to investigate the natural history of PLG-SAS and to compare it with that of HG-SAS. Our main findings are that, in the absence of AVR, patients with PLG-SAS have a significantly better spontaneous survival compared with patients with HG-SAS. This was particularly true in the subset of asymptomatic or minimally symptomatic patients, in whom transvalvular gradients were found to independently contribute to outcome. Our results also show that neither transvalvular flow nor flow rates influence outcome. Lack of prognostic impact of transvalvular flow was observed Values are n (%) or mean±SD. AVAi indicates indexed aortic valve area; GFR, glomerular filtration rate; HG-SAS, high-gradient severe aortic stenosis (SAS); LA, left atrial; LV, left ventricular; LVEDVi, LV end-diastolic volume index; NYHA, New York Heart Association; and PLG-SAS, paradoxical low-gradient SAS. July 2014 in all the subgroups examined, including those with no, mild, or severe symptoms and those with high and low transvalvular gradients. To the best of our knowledge, this is the first study to report on the natural history of PLG-SAS, all the previous investigations having concentrated on the combined end point of death and need for AVR.
Previous Studies on PLG-SAS
Our results are clearly at variance with those recently reported by Clavel et al 11 
Stenosis (SEAS) trial and with those of earlier investigators
who demonstrated a graded effect on mortality according to transvalvular gradient. 13, 14 Yet, despite these outcome differences, patients with PLG-SAS in our study displayed all the clinical and echocardiographic features typically associated with this condition, that is, small LV cavities, low LV stroke volumes and transvalvular flow rates, and high valvuloarterial impedance. It should be pointed out, however, that patients in our study were much older than in these previous studies, which could suggest that these previous series included a significant proportion of either rheumatic or congenital AS.
Since its original description by Hachicha et al 5 in 2007, the concept of PLG-SAS has been a matter of intense debate. Because PLG-SAS is frequently associated with concentric LV remodeling, low transvalvular flow, increased interstitial fibrosis, reduced long-axis LV function, 8, 9 and guarded prognosis, 5-7 this subset of SAS has been considered to represent a more advanced stage of the disease. However, a close look at published data also shows that, compared with patients with HG-SAS, those with PLG-SAS are usually older, more frequently exhibit comorbidities such as hypertension, diabetes mellitus, or atrial fibrillation, 15 more often present with concomitant coronary artery disease, and are less likely to be referred for AVR, all factors known to influence outcome in patients with heart disease, let alone in those with SAS. Because these factors have such an important impact on outcome, it is virtually impossible to statistically compensate for their presence, even by use of sophisticated statistical methods such as propensity score matching. The only way to circumvent this limitation is to use data from prospective controlled studies. Recently, Jander et al 1 used the data from the randomized SEAS trial, which enrolled 1873 patients with asymptomatic AS, defined by a peak transaortic Doppler velocity between 2.5 and 4.0 m/s, and compared the outcome of patients with PLG-SAS, HG-SAS, and moderate AS. They found that patients with PLG-SAS and those with moderate AS had similar event-free and cardiovascular survival and that both of these groups had a much better outcome compared with patients with HG-SAS. They also found that transvalvular flow did not influence outcome, irrespective of the method used to calculate LV stroke volume, be it the LV outflow tract Doppler method 1 or the Teichholz formula. 16 The results of the present study are thus in complete agreement with those of this prospective study. As in the SEAS trial, we found that patients with PLG-SAS have a better outcome compared with patients with HG-SAS and that transvalvular flow does not influence outcome. This was particularly true in asymptomatic patients without history of atrial fibrillation. To explain the diverging outcome results between their study and Jander et al, 1 Clavel et al 11 as well as Dusmenil and Pibarot 17 argued that Jander et al's patients did not exhibit the features typically seen in patients with PLG-SAS and that some patients were erroneously classified as having PLG-SAS because the authors did not use the indexed AVA to define the severity of SAS or because the LV stroke volume was underestimated in patients with PLG-SAS. Although we do not think these factors truly affected Jander et al's results in any significant way, none of them were present in our study. Indeed, our 2 patient groups had similar body sizes, SAS was defined on the basis of both nonindexed and indexed AVA, and, finally, LV stroke volume was derived from Doppler and gray-scale LV outflow tract (LVOT) parameters as recommended in the guidelines. 18, 19 Contrary to Clavel et al, 11 we made no attempt to corroborate our results to those obtained by use of the Teicholz method, because this latter is notably less accurate than the Doppler method.
Progression of PLG-SAS
The results of the present study also contradict the theory that PLG-SAS represents a more advanced, end-stage form of the disease. 5, 6 If this was true, disease progression should be associated with a progressive decrease in mean transvalvular gradients. We observed just the opposite. Indeed, careful analysis of follow-up echocardiograms indicates that ≈82% of PLG-SAS increased their mean transvalvular gradients over time, half of them even becoming HG-SAS at the end of follow-up. Similarly, we showed that most patients with HG-SAS also increased their mean transvalvular gradient over time, whereas a minority of them displayed reduced gradients at follow-up. Interestingly, in all patients whose transvalvular gradients decreased over time, the decrease was associated with a concomitant decrease in LVEF. Instead of becoming PLG-SAS, these patients developed the classical form of LF-LG-SAS because of depressed LV output and EF.
Outcome With AVR
Finally, our results, as those of recent reports, [20] [21] [22] confirm that survival in patients with PLG-SAS is improved with AVR compared with medical management. Indeed, comparing the outcome of operated and unoperated patients, we found that PLG-SAS patients benefitted from AVR, albeit to a lesser extent compared with patients with HG-SAS. Although we think that patients with PLG-SAS have a less severe form of AS compared with patients with HG-SAS (because their spontaneous outcome is better and they tend to become HG-SAS after a few years), we are convinced that the AS is severe enough in most of them to warrant and benefit from AVR once symptoms have developed.
PLG-SAS: A Moderate to Severe Form of AS
Taken together, our results indicate that PLG-SAS is a less malignant form of SAS compared with HG-SAS. We wish to speculate that it represents a transition stage between truly moderate AS (with low mean gradients and an AVA >0.6 cm 2 /m 2 ) and truly severe AS (with HG and AVA <0.6 cm 2 /m 2 ) and that the use of continuity equation explains why some patients transiently pass through a stage of PLG-SAS during their disease progression. First, the continuity equation measures the size of the functional orifice instead of that of the anatomic orifice, like the Gorlin formula. 23 This is because, in its simplified form, it neglects the coefficient of orifice contraction, a factor that compensates for the continuous convergence of fluid streamlines beyond a narrowed orifice. Under physiological flow conditions, the degree of underestimation of the anatomic orifice by the continuity equation is expected to be ≈10% to 15%. Second, in daily clinical practice, the LV stroke volume, which is at the numerator in the continuity equation, is most often calculated by using 2-dimensional echocardiographic measurements of the LVOT cross-sectional area, assuming a circular orifice. Several studies have recently shown that the LVOT is rarely circular and most often exhibits an elliptical shape, causing the LV stroke volume to be underestimated by another 10% to 15%. [24] [25] [26] This has a major impact on the classification of AS severity because many patients thought to have SAS when assuming that the LVOT is circular end up having only moderate AS when measuring the true surface of LVOT by planimetry. [25] [26] [27] Because the continuity equation-derived AVAs of PLG-SAS are usually comprised between 0.5 and 0.6 cm 2 /m 2 (or between 0.85 and 1 cm 2 ), one should expect their anatomic AVAs to be close to or even >0.6 cm 2 /m 2 when correcting for these measurement errors. This is exactly what we recently reported, using cardiac MR to measure anatomic AVAs. 28 Although in the same study HG-SAS also exhibited larger anatomic AVAs compared with continuity equation-derived AVAs, the former almost always remained <0.6 cm 2 /m 2 , thus indicating truly severe SAS, whereas half of the PLG-SAS displayed anatomic AVAs >0.6 cm 2 /m 2 . Interestingly, a recent study also demonstrated that PLG-SAS usually exhibits a lesser degree of valve calcifications as compared with HG-SAS, thus corroborating the hypothesis that these valves are at a less advanced disease stage compared with HG-SAS. 29
Limitations of the Study
The study has several limitations that should be acknowledged. First, medical management, echocardiographic surveillance, and surgical care were provided in accordance with local standards of clinical practice and after interpretation of prevailing international heart valve guidelines by the attending physicians. As such, the current report thus represents a realistic view of how physicians have managed patients with PLG-SAS while facing the clinical uncertainties about the significance of this entity. Their skepticism is reflected by their relatively low use of AVR in this population. Second, we selected 3 months as the normal window for performance of clinically indicated AVR based on the practicalities of scheduling and performing AVR in our institution. Even with shorter (1 month) or longer (6 months) time windows after diagnosis in exploratory models, outcomes remained better in PLG-SAS than in HG-SAS (data not shown). Finally, the NYHA classification is subjective, the uniformity of its criteria is certainly not perfect, and it can be difficult to use in elderly patients in whom differentiation between class I and class II symptoms is elusive. Yet, this classification is widely used and is the basis for current recommendations for surgery.
Conclusions
Our natural history study indicates that PLG-SAS is a less malignant form of AS than HG-SAS, because the spontaneous outcome of patients with PLG-SAS is better than that of HG-SAS. We further demonstrated that patients with PLG-SAS are en route toward the more severe HG-SAS form, because the majority of them evolve into HG-SAS over time. 
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